

Intravenous or Subcutaneous Natalizumab in Patients with Relapsing Remitting Multiple Sclerosis: Investigation on Efficiency and Savings—The EASIER Study

Massimo Filippi^{1,2}, Luigi Grimaldi³, Antonella Conte^{4,5,6}, Rocco Totaro⁷, Maria Rosaria Valente⁸, Simona Malucchi⁹, Franco Granella¹⁰, Cinzia Cordioli¹¹, Vincenzo Brescia Morra¹², Chiara Zanetta¹, Daria Perini¹³, Laura Santoni¹³; on behalf of the EASIER study working group

¹Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, and Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy; ²Vita-Salute San Raffaele University, Milan, Italy; ³Multiple Sclerosis Center, Fondazione Istituto G. Giglio, Cefalù (PA), Italy; ⁴Department of Human Neurosciences, Sapienza, University of Rome, Italy; ⁵Multiple Sclerosis Center Policlinico Umberto I Hospital, Rome, Italy; ⁶IRCCS Neuromed, Pozzilli (IS), Italy; ⁷Demyelinating Disease Center, Department of Neurology, San Salvatore Hospital, L'Aquila, Italy; ⁸Clinical Neurology, Santa Maria della Misericordia University Hospital and Department of Medicine, University of Udine, Udine, Italy; ⁹SCDO Neurologia, S. Luigi Gonzaga University Hospital, Orbassano (TO), Italy; ¹⁰Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy; ¹¹Multiple Sclerosis Center, ASST Spedali Civili di Brescia, Montichiari Hospital (Brescia), Italy; ¹²Multiple Sclerosis Clinical Care and Research Center, Federico II University Hospital—Department of Neuroscience (NSRO), Naples, Italy; ¹³Biogen Italia, Milan, Italy

Corresponding author: Massimo Filippi, filippi.massimo@hsr.it

	N. responders (%)	Mean (SD)	Range
Round trip distance (km traveled)	273 (92%)	73.6 (159.4)	1.5–2400
Travel time (hours)	272 (92%)	1.6 (1.4)	0–10
Means of transport	290 (98%)		
• Private vehicle	249 (86%)		
• Public transport	31 (11%)		
• Taxi	5 (2%)		
• Other	5 (2%)*		

Online Resource 6. Time and means of transport for IV procedure.

*3 on foot and 2 by plane